Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 12 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Ferro, Charles J  [Clear All Filters]
Journal Article
Ferro, C. J., Mark P. B., Kanbay M., Sarafidis P., Heine G. H., Rossignol P., et al. (2019).  Author Correction: Lipid management in patients with chronic kidney disease.. Nat Rev Nephrol. 15(2), 121.
Pappaccogli, M., Labriola L., Van der Niepen P., Pruijm M., Vogt L., Halimi J-M., et al. (2019).  Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views.. Nephrol Dial Transplant. 34(9), 1612-1615.
Sarafidis, P., Ferro C. J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. (2020).  Erratum.. Nephrol Dial Transplant. 35(8), 1452.
Sarafidis, P. A., Persu A., Agarwal, iv R., Burnier M., de Leeuw P., Ferro C. J., et al. (2017).  Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidne. Nephrol Dial Transplant. 32(4), 620-640.
Loutradis, C., Ferro C. J., & Sarafidis P. (2020).  Hypertension Management in Patients With Autosomal Dominant Polycystic Kidney Disease: Time for a Paradigm Shift?. Am J Kidney Dis. 76(5), 743.
Ferro, C. J., Mark P. B., Kanbay M., Sarafidis P., Heine G. H., Rossignol P., et al. (2018).  Lipid management in patients with chronic kidney disease.. Nat Rev Nephrol. 14(12), 727-749.
Ferro, C. J., Sarafidis P., & Ortiz A. (2020).  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.. N Engl J Med. 382(21), e65.
Raptis, V., Loutradis C., Boutou A. K., Faitatzidou D., Sioulis A., Ferro C. J., et al. (2020).  Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.. Cardiorenal Med. 1-12.
Sarafidis, P., Ferro C. J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. (2020).  SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.. Nephrol Dial Transplant. 35(10), 1825.
Sarafidis, P., Ferro C. J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. (2019).  SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.. Nephrol Dial Transplant. 34(2), 208-230.
Sarafidis, P., Loutradis C., Ferro C. J., & Ortiz A. (2020).  SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?. Am J Nephrol. 51(7), 553-555.
Loutradis, C., Sarafidis P. A., Ferro C. J., & Zoccali C. (2020).  Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management.. Nephrol Dial Transplant.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.